Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts

rttnews
2024.12.27 07:15
portai
I'm PortAI, I can summarize articles.

Syncona's investment, Achilles Therapeutics, has sold technology assets to AstraZeneca, including a commercial license for data and samples from the TRACERx non-small cell lung cancer study. AstraZeneca will pay $12 million and become the sponsor of Achilles' Material Acquisition Platform. Achilles plans to reduce its employee headcount and Board size as part of this transition.

Syncona said its investment Achilles Therapeutics has announced the sale of technology assets to AstraZeneca. The transaction include transferring of the commercial license of data and samples from the TRACERx non-small cell lung cancer study to AstraZeneca. AstraZeneca will also take over as sponsor of Achilles' Material Acquisition Platform. AstraZeneca has agreed to pay Achilles $12 million for the assets in total.

Achilles plans to undertake additional measures, including a reduction in employee headcount and a decrease in the size of its Board.

For comments and feedback contact: editorial@rttnews.com

Business News

Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.